Oric Pharmaceuticals (ORIC) just unveiled an announcement.
ORIC Pharmaceuticals has expanded its 2022 Inducement Equity Incentive Plan, adding 650,000 shares for a new total of 1.15 million shares available for equity awards to new hires. This move, which aligns with Nasdaq Listing Rules without requiring stockholder approval, aims to attract top talent by offering various equity-based incentives. The plan mirrors the company’s 2020 Equity Incentive Plan, with provisions for major corporate events like mergers and accommodates grants related to mergers or acquisitions.
Find detailed analytics on ORIC stock on TipRanks’ Stock Analysis page.
